Literature DB >> 26046055

How long should dual antiplatelet therapy be continued following implantation of drug eluting stents?

Neil Ruparelia1, Alaide Chieffo1, Antonio Colombo1.   

Abstract

Year:  2015        PMID: 26046055      PMCID: PMC4437953          DOI: 10.3978/j.issn.2305-5839.2015.02.15

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  13 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents.

Authors:  Seung-Jung Park; Duk-Woo Park; Young-Hak Kim; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Ki-Hoon Han; Seong-Wook Park; Sung-Cheol Yun; Sang-Gon Lee; Seung-Woon Rha; In-Whan Seong; Myung-Ho Jeong; Seung-Ho Hur; Nae-Hee Lee; Junghan Yoon; Joo-Young Yang; Bong-Ki Lee; Young-Jin Choi; Wook-Sung Chung; Do-Sun Lim; Sang-Sig Cheong; Kee-Sik Kim; Jei Keon Chae; Deuk-Young Nah; Doo-Soo Jeon; Ki Bae Seung; Jae-Sik Jang; Hun Sik Park; Keun Lee
Journal:  N Engl J Med       Date:  2010-03-15       Impact factor: 91.245

3.  Stent thrombosis in randomized clinical trials of drug-eluting stents.

Authors:  Laura Mauri; Wen-hua Hsieh; Joseph M Massaro; Kalon K L Ho; Ralph D'Agostino; Donald E Cutlip
Journal:  N Engl J Med       Date:  2007-02-12       Impact factor: 91.245

4.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Authors:  Fausto Feres; Ricardo A Costa; Alexandre Abizaid; Martin B Leon; J Antônio Marin-Neto; Roberto V Botelho; Spencer B King; Manuela Negoita; Minglei Liu; J Eduardo T de Paula; José A Mangione; George X Meireles; Hélio J Castello; Eduardo L Nicolela; Marco A Perin; Fernando S Devito; André Labrunie; Décio Salvadori; Marcos Gusmão; Rodolfo Staico; J Ribamar Costa; Juliana P de Castro; Andrea S Abizaid; Deepak L Bhatt
Journal:  JAMA       Date:  2013-12-18       Impact factor: 56.272

5.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

6.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

7.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.

Authors:  Antonio Colombo; Alaide Chieffo; Arian Frasheri; Roberto Garbo; Monica Masotti-Centol; Neus Salvatella; Juan Francisco Oteo Dominguez; Luigi Steffanon; Giuseppe Tarantini; Patrizia Presbitero; Alberto Menozzi; Edoardo Pucci; Josepa Mauri; Bruno Mario Cesana; Gennaro Giustino; Gennaro Sardella
Journal:  J Am Coll Cardiol       Date:  2014-09-15       Impact factor: 24.094

8.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

9.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Authors:  Deepak L Bhatt; Keith A A Fox; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Marcus D Flather; Steven M Haffner; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Danielle M Brennan; Liz Fabry-Ribaudo; Joan Booth; Eric J Topol
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

10.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Authors:  Deepak L Bhatt; Marcus D Flather; Werner Hacke; Peter B Berger; Henry R Black; William E Boden; Patrice Cacoub; Eric A Cohen; Mark A Creager; J Donald Easton; Christian W Hamm; Graeme J Hankey; S Claiborne Johnston; Koon-Hou Mak; Jean-Louis Mas; Gilles Montalescot; Thomas A Pearson; P Gabriel Steg; Steven R Steinhubl; Michael A Weber; Liz Fabry-Ribaudo; Tingfei Hu; Eric J Topol; Keith A A Fox
Journal:  J Am Coll Cardiol       Date:  2007-04-11       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.